Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilizing its proprietary MagSense® imaging technology, is pleased to announce the appointment of Dr Nina Webster as a Non-Executive Director to the Board, effective 1 September 2025.
Dr Webster brings to the Board a wealth of experience in the Australian ASX listed pharmaceutical industry, holding leadership roles over a thirty-year period. She currently serves as Managing Director and Chief Executive Officer of Demerix Ltd (ASX: DXB), a clinical-stage biopharmaceutical company, developing a portfolio of drugs to treat inflammatory diseases. Formerly the Commercial Director for Acrux Limited (ASX: ACR) and Director of Commercialisation and Intellectual Property for Immuron Limited (ASX: IMC) she brings to IBX vast experience in investor relations, strategic planning, and scientific and operational execution. Nina holds a Ph.D in Pharmaceutics, a Bachelor degree in Pharmacology, a Masters degree in Intellectual Property Law and an Executive MBA and currently also serves as Non-Executive Chairperson for SYNthesis BioVentures and as Non-Executive Director for Linear Clinical Research Limited.
“I’m honoured to join the board of Imagion Biosystems as a non-executive director and to contribute to the strategic direction and governance of the business. Imagion’s innovative approach to molecular imaging and potential early disease detection holds immense promise for improving patient outcomes. I’m excited to support the company’s mission to bring transformative diagnostic technologies to the clinic and help make a meaningful difference in people’s lives.”
The addition of Dr Webster to the IBX Board of Directors will further strengthen the Board’s capabilities as the Company continues to execute on its strategic objectives to develop and gain regulatory approval for its pipeline of MagSense® molecular imaging technologies.
Chair of the Board, Robert Proulx, said:
“We are delighted to welcome Nina to the Board. As we continue to reshape the company to better reflect the maturing state of our business, her extensive industry knowledge and board experience will be invaluable.”
